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Abstract
This study demonstrates the quantitative characteristics of the first patient-reported outcome
(PRO) tool developed for patients with nontransfusion-dependent β-thalassemia (NTDT), the
NTDT-PRO©. A multicenter validation study was performed over 24 weeks, involving 48 patients
from Italy, Lebanon, Greece, and Thailand. Most patients were female (68.8%), with a median age
of 34.5 years (range, 18-52); 66.7% were diagnosed with β-thalassemia intermedia, and median
time since diagnosis was 22 years (range, 0-43). The NTDT-PRO comprises 6 items across
2 domains (Tiredness/Weakness and Shortness of Breath [SoB]), and was valid and reliable, with
good consistency. At baseline, most patients reported symptoms as present via the NTDT-PRO,
and were highly compliant, ≥90% completing the NTDT-PRO tool. In a pairwise correlation analy-
sis, all items were positively correlated. Correlations between NTDT-PRO and existing tools—
36-Item Short Form Health Survey version 2 (SF-36v2) and Functional Assessment of Cancer
Therapy-Anemia (FACT-An)—were assessed at weeks 1, 3, and 12; robust correlations were seen
between SoB and SF-36v2-Vitality (rs = −0.53), and between SoB and Fact-An-Fatigue Experience
(rs = −0.66) at week 1. Internal consistency was high for both Tiredness/Weakness (Cronbach
alpha, 0.91) and SoB (Spearman-Brown coefficient, 0.78); intraclass correlation coefficients were
high (Tiredness/Weakness, 0.88 and 0.97; SoB, 0.92 and 0.98), demonstrating stability. Further
studies are required to fully support the validity of this tool, this study demonstrated the
usefulness of the NTDT-PRO in the clinical setting and for longitudinal clinical research, particu-
larly in trials where patient health-related quality of life is expected to change.
1 | INTRODUCTION
The hereditary blood disorder β-thalassemia affects approximately
1.5% of the global population.1 In 2008, the World Health Organiza-
tion estimated that more than 40 000 children are born annually with
β-thalassemia, of which over 20 000 are in Southeast Asia.2 More
recent estimates from Europe suggest there are approximately 7000
patients in Italy (0.012% of a total population of approximately 60 mil-
lion) and 3241 patients in Greece (0.029% of a total population of
11 million) with thalassemias.3 Modern patterns of increased migra-
tion have resulted in thalassemias becoming widespread in other
regions,4 as illustrated by a report from the Centers for Disease Con-
trol that reported that 27% of people with nontransfusion-dependent
β-thalassemia (NTDT) in North America were born overseas.5
Increasing global access to health care and the resultant increase
in life expectancy of patients with thalassemias has intensified efforts†Former employee of Celgene Corporation.
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to understand how this condition affects health-related quality of life
(HRQoL). Although disease burden varies according to whether a
patient has NTDT or transfusion-dependent thalassemia (TDT), the
impact on HRQoL and general well-being is significant.6,7
At present, the main HRQoL patient-reported outcome (PRO) tools
used in thalassemias are the 36-Item Short Form Health Survey version
2 (SF-36v2) and the Functional Assessment of Cancer Therapy-Anemia
(FACT-An) tools. These tools, particularly the SF-36v2, are not disease
specific and may include symptoms beyond those that thalassemia
patients would typically experience.
The majority of studies that investigate HRQoL using the SF-
36v2 in thalassemias focus on TDT, for example, in Italy8 and Greece.9
However, the SF-36v2 was used in a longitudinal study of 264 patients
with TDT and NTDT from the United States, Canada, and the United
Kingdom, and found that HRQoL was significantly lower in this
population compared with US norms, and interestingly, saw a higher
HRQoL associated with being transfused,10 indicating important
differences are present between TDT and NTDT patients. However,
two studies that used the Pediatric Quality of Life Inventory (PedsQL)
4.0 Generic Core scale to investigate HRQoL in Thai children with
thalassemia found that this scale gave conflicting results, with the first
finding a negative association between HRQoL and transfusion
therapy,11 and the second reporting no difference in HRQoL score
associated with type of thalassemia or clinical severity,12 emphasizing
the need for specific tools that are developed and validated for this
patient population.
The FACT-An was developed to assess HRQoL in relation to
anemia experienced by patients with cancer who are undergoing
chemotherapy,13 and so, although the patient population it was devel-
oped for may have a similar experience in some respects, there are
aspects of the NTDT patient experience that may not be adequately
captured.
In addition, while there are a number of PRO tools that have been
developed specifically for TDT patients, such as the Specific Thalasse-
mia Quality of Life Instrument (STQOLI)14 and the TranQol,15 these
focus on the impact of hospitalization associated with repeated trans-
fusion and iron chelation therapy. As patients with NTDT receive far
fewer transfusions and may experience a different symptom profile,
PRO tools to measure HRQoL in this patient group must be developed
with this in mind.
Regulatory agencies, such as the US Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA), are interested
in the development and validation of disease-specific PROs as part of
clinical outcome assessment tools for clinical research. To this end,
the NTDT-PRO© tool was developed following a rigorous, qualitative,
multicenter study, involving NTDT patients from four countries (Taher
et al., manuscript submitted for publication). The NTDT-PRO assesses
the presence or severity of the following symptoms using a numerical
rating scale ranging from 0 (“absent/minimal”) to 10 (“extreme”): Tired-
ness with or without Physical Activity, Weakness with or without
Physical Activity, and Shortness of Breath (SoB) with or without Phys-
ical Activity. These items were selected as a basis for the NTDT-PRO
following expert panel discussion and patient interviews.
The objective of the present study was to validate the NTDT-
PRO against existing HRQoL tools (SF-36v2 and FACT-An) in patients
with NTDT, and demonstrate the sensitivity and score reliability over
time of the NTDT-PRO when used in patients with NTDT.
2 | METHODS
2.1 | Evaluation of the NTDT-PRO tool
2.1.1 | Study design
The NTDT-PRO was evaluated in a prospective observational study
with no protocol-driven treatment intervention (NCT02626689).
Although the observational study included both TDT (n = 52) and
NTDT (n = 50) patients, only NTDT patients were included in this
evaluation. Patients were enrolled at five centers across four countries
(Italy, Lebanon, Greece, and two centers in Thailand); as the centers in
Lebanon and Greece were also involved in the development of the
NTDT-PRO tool (Taher et al., manuscript submitted for publication),
there was some overlap between patient populations. Eligible patients
were ≥18 years of age, had a documented diagnosis of β-thalassemia
intermedia or hemoglobin (Hb) E/β-thalassemia, Hb ≤ 10 g/dL, and
had received ≤5 red blood cell (RBC) units during the 24-week
period prior to study start. All patients were asked to complete the
NTDT-PRO daily via a handheld device, as well as the SF-36v216 and
FACT-An13 HRQoL questionnaires at baseline and every 3 weeks
thereafter for a total of ≥24 weeks.
Changes in patient health status since the start of the study were
also assessed using the Patient Global Impression of Change (PGIC)
scale once every 3 weeks.17
Three weeks was selected as a testing interval for this study to
match the dosing regimen for luspatercept, a novel therapy under
development for TDT and NTDT.
2.1.2 | Measures and procedures
The NTDT-PRO was designed to capture thalassemia-related symp-
toms over the previous 24 hr using six symptom-specific items
(Appendix in Supporting Information). An additional item was included
in the NTDT-PRO for the purposes of validation, to assess the overall
severity of the patients' thalassemia symptoms in the previous 24 hr
on a numerical scale ranging from 0 (“no symptoms”) to 10 (“very
severe symptoms”). Item scores were summarized as the mean of
nonmissing values over a 7-day period; if entries were missing for
≥4 days in any 7-day period, the weekly average was considered
missing. For the two domains, Tiredness/Weakness and SoB, the
mean and sum of items in the domain were reported.
All HRQoL questionnaires (NTDT-PRO, SF-36v2, and FACT-An)
were administered in the local language (English, Thai, Greek, Arabic, or
Italian, as appropriate). For the SF-36v2 and FACT-An, the most
recently validated local language versions were used, available from
Optum and FACIT.org, respectively. For the NTDT-PRO, the original
English version was reviewed for translation accuracy by local thalasse-
mia experts who were involved in the study (MDC for Italian, AT for
Arabic, AK for Greek, and VV for Thai; translations available on request).
Data from patients who reported “no change” (ie, a score of 4 on
a 0-10 scale) on the PGIC during weeks 3 and 12 of the study were
used to assess test–retest reliability.
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Patients with both a valid week of daily data collection at baseline
(defined as ≥4 complete diary entries in the 7-day period) and data for
≥1 questionnaire (SF-36v2, FACT-An) at baseline were included in the
analysis.
2.2 | Statistical analysis
Quantitative data, including weekly averaged NTDT-PRO items, were
summarized using descriptive statistics.
2.2.1 | Internal consistency and validity
Internal consistency was assessed by calculating the Spearman rank
correlation coefficient to evaluate the strength and direction of a
relationship between all NTDT-PRO items.
To examine internal validity, reliability was tested using the
Cronbach alpha coefficient for the Tiredness/Weakness domain score.
As SoB contained only two variables, the Spearman–Brown coeffi-
cient was calculated to determine the consistency of this measure.
2.2.2 | Validity
To investigate validity of the NTDT-PRO, correlations between the
2 NTDT-PRO domain scores (Tiredness/Weakness, and SoB) and the
domain subscale scores of existing HRQoL tools—the SF-36v2 and
the Fatigue subscale (FACIT-F) of FACT-An—were evaluated by the
Spearman–Brown correlation coefficient. Known group validity
compared eDiary scores between groups defined by the number of
comorbidities.
2.2.3 | Stability over time and sensitivity to change
To evaluate the stability of weekly averaged NTDT-PRO items and
domain scores, test–retest reliability was assessed by calculating the
intraclass correlation coefficient (ICC) over 2 intervals (weeks 1-3 and
weeks 9-12) in patients who reported no change in their overall
β-thalassemia symptoms at week 3 and 12, as measured by PGIC
score.
Sensitivity to change was assessed by examining changes in
domain scores between weeks 1 and 24 in three groups identified as
improved, no change, or worse based on PGIC score at week 24.
However, as this study was observational and did not involve an
intervention, significant changes were not anticipated.
Correlations between 0.20 and 0.39 were defined as “weak,”
correlations between 0.40 and 0.59 as “moderate,” correlations
between 0.60 and 0.79 as “strong,” and those ≥0.80 were defined as
“very strong.” Significance was defined as P < .05.
3 | RESULTS
3.1 | Measurement evaluation
3.1.1 | Patients
A total of 50 patients from five centers in four countries were
enrolled in this prospective observational study; 48 patients com-
pleted ≥1 post-baseline NTDT-PRO entry and were included in the
NTDT-PRO validation analysis. A total of 15 (31.3%), 13 (27.1%),
11 (22.9%), and 9 (18.8%) patients were enrolled in Italy, Lebanon,
Greece, and Thailand, respectively. Baseline characteristics are shown
in Table 1.
The majority of patients were female (68.8%), with a median age
of 34.5 years (range, 18-52).
During the course of the study, 7 patients (15.0%) received RBC
transfusions.
3.1.2 | NTDT-PRO distribution characteristics
NTDT-PRO item and domain scores are detailed in Table S1 in the
Supporting Information. Of the 48 patients included in the study, a
median of 37 patients (range, 30-48) completed the NTDT-PRO and
contributed data each week (≥4/7 days). The individual items with the
highest scores across the 24 weeks of testing were Tiredness with
Physical Activity (TiredPA) (range, 0-10.00) and Weakness with
Physical Activity (WeakPA) (range, 0-10.00); the lowest scores were
seen for SoB without Physical Activity (SoBNA) (range, 0-7.83).
3.1.3 | Internal consistency of NTDT-PRO
Spearman rank correlations between NTDT-PRO items are shown in
Table S2 in the Supporting Information. All pairwise correlations were
positive, and very strong correlations were found between the items
WeakPA and TiredPA (rs = 0.96), and between Weakness without
Physical Activity (WeakNA) and Tiredness without Physical Activity
(TiredNA) (rs = 0.89). Strong correlations were also found between
different constructs measuring the same level of activity, for example,
for physical activity, SoB, and both Tiredness (rs = 0.68) and Weak-
ness (rs = 0.72); similar correlations were seen for no physical activity.
Strong correlations were also observed between items measuring the
same construct but a different activity level (eg, Tiredness, rs = 0.70,
Weakness, rs = 0.69, and SoB, rs = 0.69).
The raw variable value of the Cronbach alpha (0.91) indicates high
internal consistency and reliability across the Tiredness/Weakness
domain (Table 2). The correlation within the SoB domain was also
strong (Spearman–Brown coefficient, 0.78).
TABLE 1 Patient characteristics
Patient characteristic
Analysis cohort
(N = 48)
Median age (range), years 34.5 (18-52)
Female, n (%) 33 (68.8)
Thalassemia diagnosis, n (%)
β-Thalassemia intermedia 32 (66.7)
HbE/β-thalassemia 8 (16.7)
β-Thalassemia with α-triplication 8 (16.7)
Median time since diagnosis (range), years 22 (0–43)
Hospitalization in last 3 months, n (%) NA
Median Hb (range), g/dL 8.0 (6.0-10.0)
Highest education level, n (%)
Primary/elementary 3 (6.3)
Secondary/high school 4 (8.3)
College/university 23 (47.9)
Unknown/other 18 (37.5)
Abbreviations: Hb, hemoglobin; HbE, hemoglobin E; NA, not available.
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3.1.4 | General validity of the NTDT-PRO as compared
with SF-36v2 and FACT-an
Correlation between NTDT-PRO domain scores and the SF-36v2
and FACT-An was assessed at weeks 1, 3, and 12. As the NTDT-
PRO measures symptom severity (ie, high scores indicate worse
symptoms) and the SF-36v2 and FACT-An measure function
(ie, high scores indicate better function), all correlations seen were
negative (Table 3). An exploratory factor analysis was used to
explore item groupings, which led to the combining of data from
the Tiredness and Weakness domains. The structural coefficients for
the NTDT-PRO suggested that TiredNA and WeakNA are correlated
0.892 and 0.898, respectively, with Factor 1, with loadings >0.5.
TiredPA and WeakPA are correlated 0.908 and 0.918, respectively,
with Factor 2.
The strongest correlations were seen during week 1 between the
Tiredness/Weakness domain of the NTDT-PRO and the Vitality
domain of the SF-36v2 (rs = −0.53) and the Fatigue Experience
subscale on the FACT-An (rs = −0.66). This pattern was repeated
across all time points tested, with the exception of week 12 of the
FACT-An score correlations, where the highest correlations were
between the Fatigue scale and Tiredness/Weakness (rs = −0.80), and
between the FACT-General and SoB (rs = −0.61).
At all time points investigated, the weakest correlations observed
were between the Social/Family Well-being domain of Fact-An and
the SoB domain of NTDT-PRO; the Social/Family Well-being, Func-
tional Well-being, and Anemia Symptoms domains correlated poorly
with the Tiredness/Weakness domain of the NTDT-PRO. Low corre-
lations were also observed between the SF-36v2 item Bodily Pain and
SoB, and also between General Mental Health and both SoB and
Tiredness/Weakness.
Known groups validity analysis with comorbidities showed that as
the number of comorbidities increased from 1 to 4, the ratings of
TABLE 2 Internal consistency of the NTDT-PRO© Tiredness/
Weakness domain scores at baseline
Raw variables Standardized variables
Correlation
with total
Cronbach
alpha
Correlation
with total
Cronbach
alpha
Tiredness/Weakness
domaina
– 0.91 – 0.92
TiredNA 0.79 0.89 0.82 0.89
TiredPA 0.85 0.87 0.82 0.89
WeakNA 0.76 0.90 0.79 0.90
WeakPA 0.85 0.87 0.81 0.89
Correlations >0.60 were considered “strong.”
Abbreviations: NTDT-PRO©, nontransfusion-dependent thalassemia
patient-reported outcomes measure; TiredNA, Tiredness with no Physical
Activity; TiredPA, Tiredness with Physical Activity; WeakNA, Weakness
with no Physical Activity; WeakPA, Weakness with Physical Activity.
a Spearman–Brown coefficient for the Shortness of Breath domain was
0.78 (n = 48).
TABLE 3 Convergent correlations between NTDT-PRO© domain scores and the SF-36v2 and FACT-An scales
NTDT-PRO domain
Tiredness/Weakness Shortness of Breath
Spearman correlation coefficient
Week 1
(n = 48)
Week 3
(n = 46)
Week 12
(n = 35)
Week 1
(n = 48)
Week 3
(n = 46)
Week 12
(n = 35)
SF-36v2
Physical functioning −0.41* −0.41* −0.43* −0.40* −0.42* −0.42*
Role-physical functioning −0.29 −0.30 −0.21 −0.22 −0.21 −0.21
Bodily pain −0.20 −0.20 −0.10 −0.10 −0.10 −0.10
General health perceptions −0.39* −0.40* −0.37* −0.37* −0.37* −0.37*
Vitality −0.53* −0.53* −0.45* −0.45* −0.46* −0.45*
Social functioning −0.32* −0.32 −0.14 −0.14 −0.14 −0.14
Role-emotional functioning −0.17 −0.18 −0.19 −0.19 −0.19 −0.19
General mental health −0.10 −0.12 −0.12 −0.10 −0.12 −0.10
Physical component score −0.43* −0.42 −0.28 −0.26 −0.26 −0.27
Mental component score −0.21 −0.22 −0.19 −0.19 −0.19 −0.19
FACT-An
Physical well-being −0.33 −0.62* −0.63 −0.24 −0.42* −0.60*
Social/family well-being −0.19 −0.33* −0.39* −0.08 −0.18 −0.32*
Emotional well-being −0.20 −0.35* −0.54* −0.14 −0.34* −0.48*
Functional well-being −0.16 −0.49* −0.44* −0.21 −0.37 −0.42*
Anemia symptoms (k = 7) −0.36* −0.43* −0.34* −0.24 −0.35* −0.35*
Fatigue scale −0.55 −0.70 −0.80* −0.38* −0.51* −0.58*
Fatigue experience (k = 5) −0.66* −0.75* −0.78* −0.54* −0.53* −0.54*
Fatigue impact (k = 8) −0.38* −0.61* −0.78* −0.21 −0.47* −0.60*
FACT-general −0.29 −0.59* −0.64* −0.20 −0.45* −0.61*
Correlations >0.60 were considered “strong.” “k” indicates degrees of freedom. Abbreviations: FACT, Functional Assessment of Cancer Therapy; FACT-An,
FACT-Anemia; NTDT-PRO©, nontransfusion-dependent thalassemia patient-reported outcomes measure; SF-36v2, 36-Item Short Form Health Survey
version 2.
*P < .05.
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severity for the Tiredness/Weakness, SoB items and both domain
scores increased. When the number of comorbidities was greater than
4, the severity decreased, and in some cases, below the level of sever-
ity for 0 comorbidities (eg, TiredPA, TiredNA, WeakNA, SoB domain)
(data not shown).
3.1.5 | Stability over time and sensitivity to change
The stability of the NTDT-PRO was assessed by looking at test-retest
reliability over weeks 1-3 (n = 32) and weeks 9-12 (n = 21) for the
2 NTDT-PRO domain scores in patients who reported no change by
PGIC (Table 4). ICCs were high for Tiredness/Weakness (0.88 and
0.97) and SoB (0.92 and 0.98) at all time points studied, and the aver-
age difference in scores between weeks 1 and 3 (Tiredness/Weak-
ness: 0.08; SoB: −0.06), and weeks 9 and 12 (Tiredness/Weakness:
0.01; SoB: −0.05) was small.
To assess the ability of the NTDT-PRO to detect change in health
status, PGIC responses were examined. Across the 24 weeks of the
study, the majority of patients (17 patients; 63%) reported no change
in PGIC score; 5 patients (19%) reported a worsening, and 5 patients
(19%) an improvement of the PGIC score. However, as expected in
this observational, noninterventional study, no significant change in
NTDT-PRO domain score from weeks 1 to 24 was observed, regard-
less of change in PGIC score (data not shown).
4 | DISCUSSION
Patients with NTDT experience symptoms that negatively impact
their HRQoL, and there is a paucity of specific tools to quantify this in
these patients. This study reports the multicenter validation of a novel
disease-specific PRO tool for patients with NTDT, the NTDT-PRO.
The NTDT-PRO was developed using concept-elicitation interviews,
interview discussions, cognitive interviews, and clinical input. Concept
elicitation identified 11 symptoms from which 9 were selected for
inclusion in the questionnaire. An 11-point numerical rating scale
score was given to each item. Cognitive interviews were conducted to
confirm that the selected symptoms were relevant and understood by
patients. Based on patient interviews, 6 items were selected for inclu-
sion in the final tool; TiredPA or TiredNA, WeakPA or WeakNA, and
SoB with Physical Activity (SoBPA) or SoBNA (Taher et al., manuscript
submitted for publication). Validation involved 48 patients from five
centers across four countries. It comprises 6 items across 2 domains
(Tiredness/Weakness and SoB), and an overall severity score (from
0 to 5). Our evaluation found the NTDT-PRO to be valid, reliable, and
consistent across different countries. At baseline, all items in the
NTDT-PRO were identified as present by most patients, and compli-
ance with the NTDT-PRO was generally high; the proportion of
patients able to complete the daily diary ≥4 times per week was in the
range of 60%-100%.
The items with the highest score in the NTDT-PRO were TiredPA
and WeakPA, highlighting that physical activity is often most severely
impacted for patients with NTDT.
SoBNA was the item with the lowest scores in the NTDT-PRO.
This may reflect differences in the way patients experience or report
shortness of breath, or the relative level of discomfort associated with
this symptom. Alternatively, it is possible that the levels of SoBNA are
generally low in this population. Providing patients with a clear under-
standing of the definition of shortness of breath, for example, by using
a short video clip, and how to differentiate this symptom from tired-
ness and weakness, as well as clarification on what constitutes physi-
cal activity, may therefore be beneficial.
All pairwise inter-item correlations of the NTDT-PRO were posi-
tive. Very strong correlations were found between physical-activity-
congruent Weakness and Tiredness items in particular. This indicates
a level of redundancy across Weakness and Tiredness and, in combi-
nation with the fact that these outcomes also registered the highest
scores overall, highlights the importance of including both measures in
the NTDT-PRO.
Measures of Cronbach reliability for the NTDT-PRO were encour-
aging, indicating a high degree of precision with low measurement
error. High ICC values for Tiredness/Weakness in weeks 1-3, and
across all domains in weeks 9-12, suggested good reproducibility of
this measurement.
Strong correlations were observed between the NTDT-PRO and
relevant domains of the SF-36v2 and FACT-An tools, supporting the
validity of the NTDT-PRO. The strongest correlations were observed
between the Tiredness/Weakness domain of the NTDT-PRO, and the
Vitality domain of the SF-36v2 and the Fatigue Experience subscale
of the Fact-An, confirming both the ubiquitous nature of tiredness
and weakness in patients with β-thalassemia and the likelihood that
TABLE 4 Test–retest reliability of the NTDT-PRO© domain scores
Domain score
Weeks 1-3 Weeks 9-12
(n = 32) (n = 21)
Tiredness/Weakness Shortness of Breath Tiredness/Weakness Shortness of Breath
Mean score in first week of time period (SD)a 2.84 (1.52) 1.87 (1.50) 2.51 (1.81) 1.77 (1.68)
Mean score in last week of time period (SD)b 2.76 (1.84) 1.93 (1.73) 2.50 (1.92) 1.82 (1.73)
Difference in means (SD) 0.08 (1.69) −0.06 (1.62) 0.01 (1.86) −0.05 (1.71)
P valuec .84 .88 .96 .93
ICC 0.88 0.92 0.97 0.98
Correlations >0.60 were considered “strong.” Significance was defined as P < .005.
Abbreviations: ICC, intraclass correlation coefficient; NTDT-PRO©, nontransfusion-dependent thalassemia patient-reported outcomes measure; SD, stan-
dard deviation.
a Week 1 or 9.
b Week 3 or 12.
c P value by t-test.
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the NTDT-PRO measures that same concept in the corresponding
domains/scales of the SF-36v2 and FACT-An tools.
The strength of these correlations suggests that tiredness and
weakness, and shortness of breath, as assessed by the NTDT-PRO,
represent proximal aspects of the NTDT disease experience rather
than HRQoL per se.
Patient PGIC scores were assessed at baseline and throughout
the study to provide an anchor for the data set and allow identifica-
tion of clinically important responders. While the majority (63%) of
patients reported no change in PGIC, several patients reported either
improvement (19%) or worsening (19%) of disease by PGIC. As this
study was designed as an observational, noninterventional study, sig-
nificant changes were not expected in PGIC or NTDT-PRO scores.
The NTDT-PRO tool was developed in a population of patients
with a diagnosis of nontransfusion-dependent β-thalassemia con-
firmed by chart review; it is likely that it would yield similar results in
patients with nontransfusion-dependent α-thalassemia; however, fur-
ther research would be required before this tool can be recommended
for use in other NTDT populations. This study did not assess the
responsiveness of the NTDT-PRO to treatment, and future studies to
validate this tool in an interventional setting will provide further
insight into the sensitivity to change of the NTDT-PRO. The ecological
validity, that is, the generalizability of the tool to a real-world setting,
such as community-based centers versus academic centers, has also
not been assessed. Further validation of the NTDT-PRO in these real-
world settings will be important to increase the utility of the tool.
This study supports the validity of the NTDT-PRO tool as appro-
priate and stable for assessment of key symptoms in patients with
NTDT. The NTDT-PRO tool takes under 5 min to complete, less than
the time required both for the SF-36v2 and for the FACT-An (around
10 min for each). Moreover, this score provides a novel, disease-
specific tool focusing on symptoms that were identified as significant
to patients with NTDT, both according to physician insight and from
self-report of patient experience. The NTDT-PRO could, therefore, be
used in routine clinical evaluation and to support clinical trials
investigating new pharmacologic agents that might ameliorate clinical
anemia and improve quality of life.
For the first time in the area of clinical hematology, both the
development (Taher et al., manuscript submitted for publication) and
validation of the NTDT-PRO were conducted across multiple coun-
tries and in multiple languages, with a high level of reliability and
reproducibility. As thalassemia, particularly NTDT, is prevalent across
the world, this NTDT-PRO tool could be of clinical use worldwide.
Further interventional studies to confirm the psychometric properties
of the NTDT-PRO, validate the sensitivity to change, and determine
what constitutes the minimal clinically important difference and a clin-
ically important responder in this population are ongoing.
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